Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept

Rheumatology

Volumn 50, Issue 10, 2011, Pages 1814-1822

  Blache, Céline ^a   Lequerré, Thierry ^a,b   Roucheux, Arnaud ^b   Beutheu, Stéphanie ^a   Dedreux, Ingrid ^b   Jacquot, Serge ^a,b   Le Loët, Xavier ^a,b   Boyer, Olivier ^a,b   Vittecoq, Olivier ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Adalimumab; Etanercept; Regulatory T cells; Rheumatoid arthritis; TNF blocking agent

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE;

ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL COUNT; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 80053140303     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker183     Document Type: Article

References (24)

1. + regulatory T-cell functions in rheumatoid arthritis by Treg counts are not affected by ADA or ETA in RA cytokine-targeted monoclonal antibody therapy. Drug Discov Today 2007;12:548-52.
2. Sakaguchi S, Yamaguchi T, Nomura T et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
3. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32.
4. +) T helper cells. J Exp Med 2002;196:255-60.
5. + regulatory T cells. Nat Immunol 2003;4:330-6.
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
7. Seddiki N, Santher-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700.
8. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33:215-23.
9. + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140:360-7.
10. bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004;172: 6435-43.
11. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200: 277-85.
12. +CD25hi T-regulatory cells. Blood 2006;108:253-61.
13. Flores-Borja F, Jury EC, Mauri C et al. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008;105: 19396-401.
14. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double- blind randomised controlled trial. Lancet 2004;363: 675-81.
15. Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52: 1020-30.
16. ++ T cells is discriminated by membrane-bound tumor necrosis factor alpha. Arthritis Rheum 2008;58:1609-18.
17. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9.
18. Vigna-Pérez M, Abud-Mendoza C, Portillo-Salazar H et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005;141:372-80.
19. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
20. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
21. + regulatory T cells in adult life. Blood 2006;107:2830-8.
22. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol 2008; 38:921-4.
23. Dombrecht EJ, Aerts NE, Schuerwegh AJ et al. Influence of anti-tumor necrosis factor therapy (adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exp Rheumatol 2006;24:31-7.
24. + regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6:R335-46.